- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pfizer-Merck Immunooncology Collaboration Announced
Following the news that pembrolizumab may be approved earlier than expected, Pfizer and Merck have announced a partnership to evaluate the PD-1 inhibitor in combination with Pfizer's Xalkori.
Two Big Pharma heavyweights in the cancer field are joining hands on yet another immuno-oncology pact, adding to a long string of combination drug partnerships that promise to amp up the impact of a growing portfolio of cancer therapies. In today's case, Merck ($MRK) and Pfizer ($PFE) have struck a deal to add the PD-1 superstar pembrolizumab to Xalkori for ALK-positive cases of advanced non-small cell lung cancer.
The companies are keeping the terms of the deal private, but Pfizer will take the lead on the Phase Ib study, which launches sometime next year. Both companies now have a full plate of combination pacts to explore. Earlier they had agreed to match Pfizer's Inlyta with pembrolizumab for renal cell carcinoma. Another trial will add Pfizer's experimental drug PF-2566, an IO treatment that targets the human 4-1BB receptor, for multiple cancers.
Read the complete report: http://bit.ly/XPIGkM
Source: FierceBiotech
News of the early approval of pembrolizumab: http://bit.ly/1zzj7jp
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
